Skip to main content

Table 1 Characteristics and health status of COPD subjects at baseline according to the exacerbation status during the 6-month follow-up*

From: Effect of exacerbations on health status in subjects with chronic obstructive pulmonary disease

  With exacerbation
(n = 48)
Without exacerbation
(n = 108)
P value
Gender (M/F) 46/2 103/5 0.90
Age, yrs 71.4 ± 7.0 71.4 ± 6.0 0.95
pre-bronchodilator FEV1, L 0.83 ± 0.22 1.04 ± 0.37 < 0.001
pre-bronchodilator FEV1, %pred. 32.8 ± 9.1 40.5 ± 13.3 <0.001
pre-bronchodilator FVC, L 2.06 ± 0.42 2.26 ± 0.66 0.049
post-bronchodilator FEV1, L 1.04 ± 0.26 1.26 ± 0.43 <0.001
post-bronchodilator FEV1, %pred. 40.7 ± 10.9 49.3 ± 15.4 <0.001
post-bronchodilator FVC, L 2.50 ± 0.46 2.67 ± 0.66 0.10
Current/former-smokers 10/38 18/90 0.53
Using inhaled corticosteroids, % 54.2 49.1 0.57
TLC, L 5.78 ± 0.88 5.60 ± 1.00 0.28
RV/TLC, % 50.4 ± 7.3 47.0 ± 8.7 0.02
KCO, mmol·min-1·kPa-1·L-1 0.83 ± 0.38 0.99 ± 0.39 0.02
PaO2, kPa 9.71 ± 1.20 9.81 ± 1.17 0.62
PaCO2, kPa 5.48 ± 0.41 5.40 ± 0.52 0.37
CRQ**    
   Dyspnea (5–35) 25.4 ± 5.4 27.0 ± 5.2 0.09
   Fatigue (4–28) 19.0 ± 5.3 20.3 ± 5.4 0.19
   Emotion (7–49) 37.4 ± 8.5 39.4 ± 8.6 0.18
   Mastery (4–28) 22.0 ± 4.4 22.4 ± 4.6 0.60
   Total (20–140) 103.8 ± 20.2 109.0 ± 20.3 0.14
SGRQ (0–100)    
   Symptoms 53.7 ± 20.7 45.2 ± 22.8 0.03
   Activity 54.4 ± 19.8 43.1 ± 23.3 0.003
   Impacts 32.8 ± 18.9 26.9 ± 19.1 0.08
   Total score 44.5 ± 17.7 36.2 ± 19.4 0.013
  1. * The data are presented as mean ± SD unless otherwise stated. ** Higher scores indicate a better quality of life on the CRQ. † Higher scores indicate a poorer health status on the SGRQ.